Profil
Patrick J.
Crutcher is currently the President & Chief Executive Officer at AlmataBio, Inc. Previously, he served as the Chairman & President at Ichorion Therapeutics, Inc. from 2017 to 2018.
He also worked as the Chief Strategy Officer at Avalo Therapeutics, Inc. in 2019.
Mr. Crutcher holds a graduate degree from the University of California, Los Angeles and an undergraduate degree from the University of Illinois.
Postes actifs de Patrick Crutcher
| Sociétés | Poste | Début |
|---|
Anciens postes connus de Patrick Crutcher
| Sociétés | Poste | Fin |
|---|---|---|
| AVALO THERAPEUTICS, INC. | Corporate Officer/Principal | 01/11/2019 |
Ichorion Therapeutics, Inc.
 Ichorion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ichorion Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of treatments for rare diseases. It focuses on a pipeline of genetically-targeted therapies for inherited metabolic disorders known as Inborn Errors of Metabolism. The company was founded by Stephen Thomas on July 7, 2017 and is headquartered in New York, NY. | Directeur Général | 01/09/2018 |
Formation de Patrick Crutcher
| University of Illinois | Undergraduate Degree |
| University of California, Los Angeles | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| AVALO THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Ichorion Therapeutics, Inc.
Ichorion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ichorion Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of treatments for rare diseases. It focuses on a pipeline of genetically-targeted therapies for inherited metabolic disorders known as Inborn Errors of Metabolism. The company was founded by Stephen Thomas on July 7, 2017 and is headquartered in New York, NY. | Health Technology |
